ImmuPharma Advances P140 Platform with Key Discoveries and Strategic Partnerships

ImmuPharma ( (GB:IMM) ) has issued an update.

ImmuPharma PLC announced its final results for 2024, highlighting significant advancements in its P140 autoimmune technology platform. The company reported a reduced loss for the period and a successful fundraising effort. Key developments include groundbreaking preclinical research that enhances diagnostics and treatment monitoring for autoimmune diseases, and evidence supporting P140’s unique mechanism of action, which is non-immunosuppressive. These advancements have strengthened ImmuPharma’s intellectual property portfolio and opened discussions with potential global commercial partners, positioning the company for future growth and impact in the autoimmune disease treatment market.

More about ImmuPharma

ImmuPharma PLC is a specialist drug discovery and development company focused on creating innovative therapies for autoimmune diseases. The company’s primary product is the P140 technology platform, which aims to provide novel treatments for conditions such as systemic lupus erythematosus (SLE) by restoring immune system balance.

Average Trading Volume: 3,086,600

Technical Sentiment Signal: Buy

Current Market Cap: £16.77M

See more data about IMM stock on TipRanks’ Stock Analysis page.